Download Study on genetic polymorphisms (SNPs)

Pharmacogenomics in Japan
Hiroshi Gushima
Director
R&D Planning & Administration Department
Yamanouchi Pharmaceutical Co., Ltd.
From reports, “Pharmacogenomics” and “Observation on genomics-based medicine”
issued by the Japan Health Sciences Foundation
Application of Pharmacogenomics

To identify the genes or loci which are
involved in determining the responsiveness
to a given drug

to distinguish responders and non-responders
by Dr. Jim Wei, FDA, 2000
KH symposium, October 23, 2001
Impacts of Pharmacogenomics
on Medical Care

Delivery of high quality drug in short and
reliable R&D process

Improvement of drug efficacies and reduction
of adverse events

Development and evolution of healthcare
services to be tailor-made medicine
KH symposium, October 23, 2001
Construction of Infrastructure for
Pharmacogenomics by Government
 Millennium Project


Therapeutic related gene and genome-wide SNPs
Post genome project: protein structural and
functional analyses
 Ethical considerations in genome research


Basic principles for human genome research
Ethical guidelines for human genome and gene research
KH symposium, October 23, 2001
Pharmacogenomics
by Private sector in Japan
 Challenging
 in the Millennium Project led by government
 in the Pharma SNP Consortium led by JPMA
 with venture enterprises
 Establishment of ethics committees on
genome research
 Fostering of bio-informatists and researchers
KH symposium, October 23, 2001
Issues of Pharmacogenomics
in Japan

Lagging of the pharmacogenomic approach in drug
research and development

Challenges on drug development in private sector

Immature environment
 Understanding
and support of clinical investigators
 Public acceptance
 Reasonable and more flexible usage of the guideline
for genome research

Fostering of bio-informatists and researchers
KH symposium, October 23, 2001